Vendor review
Shandong Aishi Biotechnology reviews
Shandong Aishi Biotechnology reviews from 87 independent lab tests (Tirzepatide, Retatrutide and GHK-Cu): grade A, purity and fill accuracy. Is Shandong Aishi Biotechnology legit? See what its vials showed.
Grade A87 independent lab tests0 peptides listedShips from China
What the lab tests show
87 tests on record, newest first. Scores are purity divided by ten.
| Date | Product | Purity | Quantity | Identity | Certificate |
|---|---|---|---|---|---|
| Sep 24, 2026 | GHK-Cu | 99.9 % | 46.6 mg of 50 mg (-7 %) | Pass | View |
| Sep 23, 2026 | GHK-Cu | 99.9 % | 51.6 mg of 50 mg (3 %) | Pass | View |
| Sep 23, 2026 | Retatrutide | 98.8 % | 8.71 mg of 10 mg (-13 %) | Pass | View |
| Sep 14, 2026 | Tirzepatide | 99.9 % | 35.8 mg of 30 mg (19 %) | Pass | View |
| Sep 9, 2026 | GHK-Cu | 99.8 % | 45.4 mg of 50 mg (-9 %) | Pass | View |
| Aug 26, 2026 | Tirzepatide | 99.9 % | 19.1 mg of 20 mg (-4 %) | Pass | View |
| Aug 3, 2026 | HGH | 36 IU | Fail | View | |
| Aug 3, 2026 | HGH | 99.9 % | 20.8 IU of 24 IU (-13 %) | Pass | View |
| Jun 26, 2026 | GHK-Cu | 99.6 % | 64.2 mg of 50 mg (28 %) | Pass | View |
| Jun 17, 2026 | Tirzepatide | 99.8 % | 10.9 mg of 10 mg (9 %) | Pass | View |
| Jun 17, 2026 | Retatrutide | 98.2 % | 14.4 mg of 15 mg (-4 %) | Pass | View |
| Jun 17, 2026 | GHK-Cu | 99.7 % | 98.1 mg of 100 mg (-2 %) | Pass | View |
| Jun 17, 2026 | Tesamorelin | 99.6 % | 5.6 mg of 5 mg (12 %) | Pass | View |
| Jun 16, 2026 | GHK-Cu | 99.9 % | 49.4 mg of 50 mg (-1 %) | Pass | View |
| Jun 16, 2026 | Tirzepatide | 99.9 % | 27.7 mg of 30 mg (-8 %) | Pass | View |
| Jun 15, 2026 | HGH | 24 IU | Fail | View | |
| Jun 5, 2026 | Retatrutide | 99.9 % | 19.4 mg of 20 mg (-3 %) | Pass | View |
| Jun 2, 2026 | Retatrutide | 99.9 % | 27.6 mg of 30 mg (-8 %) | Pass | View |
| Jun 2, 2026 | Tirzepatide | 99.6 % | 53.9 mg of 50 mg (8 %) | Pass | View |
| Jun 2, 2026 | GHK-Cu | 99.8 % | 48.1 mg of 50 mg (-4 %) | Pass | View |
| May 27, 2026 | Tesamorelin | 99.1 % | 4.65 mg of 10 mg (-54 %) | Pass | View |
| May 8, 2026 | Retatrutide | 99.9 % | 10.4 mg of 10 mg (4 %) | Pass | View |
| May 6, 2026 | Retatrutide | 99.9 % | 5.06 mg of 5 mg (1 %) | Pass | View |
| May 6, 2026 | Ipamorelin | 99.9 % | 4.83 mg of 5 mg (-3 %) | Pass | View |
| Apr 30, 2026 | Retatrutide | 99.8 % | 20.5 mg of 20 mg (2 %) | Pass | View |
| Mar 6, 2026 | Tirzepatide | 99.9 % | 24.7 mg of 30 mg (-18 %) | Pass | View |
| Mar 6, 2026 | Retatrutide | 99.9 % | 19 mg of 20 mg (-5 %) | Pass | View |
| Mar 6, 2026 | Tirzepatide | 99.9 % | 25.4 mg of 30 mg (-15 %) | Pass | View |
| Mar 6, 2026 | Retatrutide | 99.9 % | 4.39 mg of 5 mg (-12 %) | Pass | View |
| Mar 6, 2026 | GHK-Cu | 99.9 % | 84.7 mg of 100 mg (-15 %) | Pass | View |
| Mar 6, 2026 | GHK-Cu | 99.8 % | 52.8 mg of 50 mg (6 %) | Pass | View |
| Mar 6, 2026 | GHK-Cu | 99.9 % | 76.6 mg of 100 mg (-23 %) | Pass | View |
| Mar 6, 2026 | Tirzepatide | 99.9 % | 24.7 mg of 20 mg (24 %) | Pass | View |
| Mar 6, 2026 | BPC-157 | 99.9 % | 10.4 mg of 10 mg (4 %) | Pass | View |
| Mar 3, 2026 | Tirzepatide | 99.9 % | 26.7 mg of 30 mg (-11 %) | Pass | View |
| Mar 1, 2026 | Retatrutide | 99.7 % | 9.8 mg of 10 mg (-2 %) | Pass | View |
| Feb 26, 2026 | Tirzepatide | 99.88 % | 33.5 mg of 30 mg (12 %) | Pass | View |
| Feb 22, 2026 | Retatrutide | 99.9 % | 20.6 mg of 20 mg (3 %) | Pass | View |
| Feb 22, 2026 | GHK-Cu | 99.9 % | 88.5 mg of 100 mg (-12 %) | Pass | View |
| Feb 22, 2026 | GHK-Cu | 99.6 % | 98.7 mg of 100 mg (-1 %) | Pass | View |
| Feb 20, 2026 | Tesamorelin | 99.7 % | 5.23 mg of 10 mg (-48 %) | Pass | View |
| Feb 20, 2026 | Tirzepatide | 99.9 % | 15.6 mg of 10 mg (56 %) | Pass | View |
| Feb 20, 2026 | Tirzepatide | 99.78 % | 46.2 mg of 50 mg (-8 %) | Pass | View |
| Feb 20, 2026 | Tirzepatide | 99.9 % | 22.6 mg of 20 mg (13 %) | Pass | View |
| Feb 18, 2026 | GHK-Cu | 99.9 % | 42.7 mg of 50 mg (-15 %) | Pass | View |
| Feb 18, 2026 | Tirzepatide | 99.9 % | 5.2 mg of 5 mg (4 %) | Pass | View |
| Feb 18, 2026 | BPC-157 | 99.9 % | 5.07 mg of 5 mg (1 %) | Pass | View |
| Feb 16, 2026 | Retatrutide | 99.9 % | 10.8 mg of 10 mg (8 %) | Pass | View |
| Feb 16, 2026 | Retatrutide | 96.82 % | 2.81 mg of 10 mg (-72 %) | Pass | View |
| Feb 15, 2026 | Tirzepatide | 99.8 % | 35.5 mg of 30 mg (18 %) | Pass | View |
| Feb 4, 2026 | Tesamorelin | 99.56 % | 11.1 mg of 10 mg (11 %) | Pass | View |
| Feb 4, 2026 | Retatrutide | 99.7 % | 10 mg of 10 mg (0 %) | Pass | View |
| Feb 4, 2026 | Tirzepatide | 99.8 % | 15 mg of 15 mg (0 %) | Pass | View |
| Feb 2, 2026 | Tesamorelin | 99.9 % | 10.7 mg of 10 mg (7 %) | Pass | View |
| Feb 2, 2026 | Tirzepatide | 99.04 % | 42.4 mg of 40 mg (6 %) | Pass | View |
| Feb 2, 2026 | Tirzepatide | 99.13 % | 36.9 mg of 30 mg (23 %) | Pass | View |
| Feb 2, 2026 | Ipamorelin | 99.9 % | 9.8 mg of 10 mg (-2 %) | Pass | View |
| Feb 2, 2026 | Tirzepatide | 99.17 % | 21.4 mg of 20 mg (7 %) | Pass | View |
| Jan 29, 2026 | Retatrutide | 99.53 % | 37.3 mg of 36 mg (4 %) | Pass | View |
| Jan 29, 2026 | Retatrutide | 98.85 % | 10.9 mg of 10 mg (9 %) | Pass | View |
What Shandong Aishi Biotechnology sells
No current listings on record.
About Shandong Aishi Biotechnology
Finnrick has tested 87 samples from Shandong Aishi Biotechnology across 7 products.